KOSDAQ Coverage Gaps 2026: 52 Names Analysts Actually Follow — And the 9 Small-Caps Hiding in Plain Sight

Thu, 23 Apr 2026 18:00:00 +0900

Series — KOSDAQ Structural 2026 (Part 4 of 4, bonus) ① Capital Inflow Triggers & VC Ranking — the policy setup ② IPO Class of 2023-2026: Where the Tenbaggers Live — the post-IPO winners ③ KR Tenbaggers Full 10× Census — the realized 3-year winners ④ This post — where sell-side isn’t yet, and why that matters

The Premise

If tenbaggers cluster, so does sell-side attention. And the gap between where analysts publish and where the structural winners sit is where variant perception lives.

We pulled every broker report filed to Hankyung Consensus (한경컨센서스) over the trailing 3 months — Jan 23 to Apr 23, 2026 — across 11 brokers that feed the platform (LS, Eugene, SK, iM, Meritz, Yuanta, Hanwha, IBK, Daishin, Sangsangin, KoreaIR). Only 52 KOSDAQ names got ≥2 broker coverage in that window.

That’s out of ~1,777 KOSDAQ stocks.

Data Caveat (Say It Once, Loud)

Hankyung does not include Samsung, Mirae Asset, Kiwoom, NH, Hana, Shinhan, KB, Korea Investment, DB, or Daol — 10+ major houses. So “2 brokers on Hankyung” typically maps to 4-6 actual brokers in the real market. That matters for a few names below where the published count understates the truth.

[Fact] 52 names passed the 2-broker / 3-month threshold on Hankyung
[Inference] True market-wide coverage is ~1.8-2.5× the reported number
[Blocked] Target-price consensus and recommendation distributions are not computable from this dataset (needs FnGuide)

The Sector Map — 52 Names, 8 Buckets

Sector	Count	Share	Notable density
Electronics / Semis	13	25%	Ecopro BM, Leeno, Duksan Neolux
Machinery / Equipment	10	19%	Wonik IPS, ISC, Tes
Bio / Pharma	10	19%	ABL Bio, Classys, Hugel
Media / Ent / Games	6	12%	SM (8 brokers, 14 reports), YG (7/12), JYP (5/7)
IT Services / SW	5	10%	Pearl Abyss, Dear U, Neowiz
Defense	3	6%	Daeyang, Victek, Coats Technologies
Education / Services	2	4%	Megastudy, JLS
Financial / Consumer / Chemical	3	6%	Hecto Financial, Silicon2, Sungeel HiTech

Market-cap distribution:

L (>1T KRW): 27 names (52%)
M (300B-1T): 16 (31%)
S (100-300B): 8 (15%)
XS (<100B): 1 (2%)

The structurally interesting bucket is the 9 small-caps ≤300B KRW with ≥2 brokers. That combination — small enough to be inefficient, covered enough to have a publishable thesis — is where variant perception can actually be framed.

The 9 Small-Caps

Ticker	Name	Cap (B KRW)	Coverage	Thesis keyword
357580	Amosense	216	SK, Yuanta (+ Hanyang)	SOFC ceramic substrate, fuel cell / auto electronics
448710	Coats Technologies	124	iM, Eugene, Yuanta (+ Hi)	K2 SBC, Cheongung-II, ASP lift, site visits
108380	Daeyang Electric	298	IBK, LS	14-year range breakout, corporate restructuring
321550	Tiumbio	271	Eugene, KoreaIR	Merigolix Europe licensing inflection
065450	Victek	169	SK, Yuanta	Structural EW niche, new growth drivers
232680	Raon Robotics	213	Yuanta, KoreaIR	Semi fab robots, global expansion
263860	Genians	145	Eugene, KoreaIR	NAC/EDR #1, capex-to-operating-leverage
078890	Gaon Group	125	Meritz, Yuanta	STB NDR, strong demand, earnings turn
040420	Sangsang JLS	94	LS, KoreaIR	Education dividend, margin improvement

One structural read-through: 5 of 9 have KoreaIR Council as one of the two “brokers.” KoreaIR publishes sponsored/initiation research — quality varies, but it’s not an independent second opinion. Subtract that, and the real publishable-thesis count drops to 1 broker + initiation note for many of these. That’s thinner than the raw coverage implies — and thinner coverage is where variant perception is cheapest.

Six Thesis Archetypes

A — Defense Export, Tier-2 Beneficiary (2 names)

Name	Choke point	Priced-in
Coats Technologies	Sole domestic supplier of K2 SBC; Cheongung-II integrated operating computer localization complete	Medium
Victek	Electronic warfare (EW) domestic niche	Medium-low

Coats Technologies printed 1,190B KRW order backlog at 2024Q3 with UAE / Saudi / Iraq entering volume production in 2026. [Fact] Cheongung-II hit 100% intercept rate on eight cruise missiles in a March 2026 UAE engagement (MBC, FT) — the kind of live-combat validation that historically re-rates defense export names globally.

The tier-1 names (Hyundai Rotem, LIG Nex1) are priced-in. Coats is the lock-in supplier one layer down the stack.

Victek’s “structurally growing EW niche” is softer — analyst defensive framing rather than a numbers-backed thesis. Needs quant validation.

B — AI / Datacenter Power Chain (1 name)

Name	Choke point	Priced-in
Amosense	Sole domestic manufacturer of ceramic electrolyte substrate for Bloom Energy SOFCs	Low

This is the strongest choke-point candidate in the entire set.

Bloom-Oracle 2.8GW agreement (Apr 2026)
Bloom-AEP $2.65B agreement (Jan 2026)
Hanyang Securities: Amosense SOFC revenue 100B KRW in 2026 → 400B KRW in 2027 (4×)
Bloom’s strategic China supply-chain diversification = direct Amosense tailwind
Peers in the Bloom supply chain (Vinatech, Kosess) have already rallied; Amosense is still sitting at 160-220B KRW market cap

This is the classic NRE-to-volume J-curve: 2024-25 = pilot, 2026 = first volume (100B), 2027 = scale (400B). Same shape as the ADT / Gaonchips cycle a few years back. The consensus hasn’t reflected the 2027 step-up yet.

C — Value-Up / Activist (1 name)

Name	Trigger	Priced-in
Daeyang Electric	Quad Asset Management shareholder proposal → Jan 29, 2026 disclosure: Daeyang-Jeonjang stake acquisition, subsidiary conversion	Medium-high

Broke a 14-year range in January. IBK target price 46,000 KRW (+20% revision), LS 40,000. Already hit 52-week high at 31,500 and is digesting. Most of the first leg is priced in. The second catalyst — actual buyback cancellation or dividend expansion — is the checkpoint.

Warning: don’t generalize this into “value-up = automatic rerating.” It worked here because the activist forced a specific, disclosable action. Without that forcing function, a governance thesis is just vibes.

D — Biotech Pipeline Inflection (1 name)

Name	Event	Priced-in
Tiumbio	Merigolix Europe licensing	Low

Binary. L/O lands → re-rating. L/O falls through → drawdown. Typical small-cap biotech shape. Latest publishable research is Eugene’s Apr 13 NDR note; KoreaIR’s piece is from Feb 25. [Speculation] on the outcome.

E — Niche Tech Leadership (3 names)

Name	Positioning	Priced-in
Raon Robotics	Global push in semi-fab robots	Low
Genians	NAC / EDR #1 domestically	Medium
Gaon Group	STB / networking earnings turn	Medium

These are the “quality small-cap” cluster. Raon’s “aspirations” framing tells you earnings are still lagging the story. Genians is a slow compounder — the edge is in the operating-leverage step-up if enterprise security capex cycle turns. Gaon is cycle-sensitive; NDR narrative (“strong demand”) needs P&L confirmation.

F — Dividend / Low-Growth (1 name)

Name	Positioning	Priced-in
Sangsang JLS	Education sector dividend play	Medium

94B KRW cap, decent dividend + improving margins, minimal growth. Not alpha — carry. Belongs in a yield sleeve, not a variant-perception book.

Variant Perception Ranking

Rank	Name	Trade type	Core reason	Horizon
1	Amosense (357580)	Idiosyncratic Alpha	Bloom supply-chain peers already rallied, Amosense lagging; 4× SOFC revenue step-up 2026→2027 not in consensus	6-12M
2	Coats Technologies (448710)	Idiosyncratic Alpha	Tier-1 defense priced-in; sole-supplier SBC lock-in + Cheongung-II global demand post-UAE validation	6-12M
3	Tiumbio (321550)	Speculation	Europe L/O binary — re-rates hard up or hard down	3-9M
4	Raon Robotics (232680)	Beta Trade	Semi-fab capex cycle exposure	12M+
5	Victek (065450)	Idiosyncratic Alpha	EW niche — needs numbers	12M+
6	Genians (263860)	Quality Compounder	Slow security-SW compounder	24M+
7	Gaon Group (078890)	Beta Trade	STB earnings turn — cycle-sensitive	6M
8	Daeyang Electric (108380)	Idiosyncratic Alpha (late)	First-leg done; waiting on second catalyst	3-6M
9	Sangsang JLS (040420)	Carry	Dividend play; not alpha	Indefinite

Other Structural Observations

Entertainment coverage is anomalously deep. SM at 8 brokers / 14 reports and YG at 7 / 12 is mid-cap-index-level density. Within the same sector, SAMG Entertainment at 2 / 2 is the “quasi-coverage gap” candidate — covered enough to have a framework, sparse enough that a re-rating under a hit IP thesis has room to run.

Structural coverage deserts — consumer, chemicals, autos, transport, construction. 0-1 names each. Partly because KOSDAQ listings in those sectors are sparse to begin with, but for names like Silicon2 (3T KRW cap, single broker coverage), the absence of peer benchmarking is a real risk — analysts cannot triangulate without comparables.

Defense small-caps are getting real traffic. Three names in the 100-300B cap range, all with recent notes (Apr 7, Apr 15, Apr 17). Coats Technologies at 124B KRW with 3 brokers is coverage-density-per-cap that typically precedes promotion into the sell-side consensus proper.

KoreaIR-Council inflation. ~5 of the 9 small-caps have one of their two “covers” as KoreaIR Council. That is an initiation-style sponsored research product — useful, but not independent second-opinion coverage. Filtering it out, most of these names are really “1 broker + initiation note” — meaningfully thinner than the raw count suggests, and a better reflection of where the variant-perception opportunity actually lives.

Invalidation Triggers

Because small-cap theses die quietly, write the kill condition up front.

Name	Kill trigger
Amosense	Bloom-Oracle / AEP supply schedule slips ≥6 months; or Bloom re-expands Chinese supply publicly
Coats Technologies	2026H1 order backlog drops below 1,000B; Polish K2 Phase-2 contract negotiations break
Daeyang Electric	No concrete buyback-cancellation or dividend-expansion announcement by end-2026
Tiumbio	Merigolix Europe negotiations halt, or clinical data turns negative

TL;DR

KOSDAQ sell-side coverage is concentrated in 52 names — just 3% of the index. Within that, 9 small-caps (≤300B KRW) cluster into 6 thesis archetypes: defense tier-2, AI power chain, activist value-up, biotech inflection, niche tech, and dividend carry.

Two names stand out on the choke-point / priced-in matrix:

Amosense — Bloom Energy ceramic-substrate bottleneck, 4× revenue step-up not in consensus
Coats Technologies — K2 SBC sole supplier + Cheongung-II live-combat validation

Daeyang Electric already ran on the value-up story — most of the first-leg move is priced in; the second catalyst is the decision point. The rest sit in weaker variant-perception positions: Tiumbio is binary, Raon is a beta trade, Sangsang JLS is carry.

If sell-side hasn’t written it down, it isn’t priced. These 9 names are the cheapest option we found on that asymmetry.

This bonus post closes the KOSDAQ Structural 2026 series. Part 1: VC ranking. Part 2: IPO tenbagger class. Part 3: Full 10× census.

Nothing here is investment advice. All names covered are idea-generation candidates for further diligence.

Sell-Side-Coverage on Korea Invest Insights